Tempus

Chicago, United States· Est. 2015

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $995M

Overview

Founded in 2015 and headquartered in Chicago, Tempus is a leader in AI-powered precision medicine, operating at the intersection of diagnostics, data, and software. The company's core asset is its massive, multimodal real-world data platform, which it leverages to provide genomic testing, clinical trial matching, and AI-driven analytical tools for providers and biopharma partners. Tempus has established significant market penetration with oncologists and academic centers, secured numerous pharma partnerships, and is expanding its regulatory footprint with FDA-cleared diagnostic devices, positioning itself as a critical infrastructure player in modernizing healthcare.

OncologyNeurologyPsychiatryCardiologyRadiology

Technology Platform

AI-powered operating system integrating a large-scale library of multimodal real-world data (clinical, molecular, imaging) with analytical tools, EHR-integrated software, and algorithmic models for precision medicine.

Funding History

Total raised:$995M

Series G$275MBaillie GiffordJun 15, 2022

Series F$200MBaillie GiffordMay 15, 2021

Series E$100MBaillie GiffordJul 15, 2020

Series D$200MBaillie GiffordDec 15, 2019

Opportunities

Massive market expansion beyond oncology into neurology, cardiology, and psychiatry represents a significant growth vector.

The increasing demand from biopharma for high-quality real-world data and AI-powered biomarkers for drug development creates a substantial and sticky revenue stream.

Regulatory clearances for its assays and algorithms can open up new clinical markets and reinforce its value proposition.

Risk Factors

Faces intense competition from established diagnostic giants and agile AI startups.

Regulatory and reimbursement landscapes for advanced diagnostics and AI software are complex and subject to change.

The capital-intensive business model of aggregating and structuring vast datasets requires continuous fundraising and poses a challenge to achieving profitability.

Competitive Landscape

Tempus competes in several segments: in comprehensive genomic profiling against Foundation Medicine (Roche) and Guardant Health; in real-world data/analytics against Flatiron Health (Roche), IQVIA, and ConcertAI; and in AI-powered clinical decision support against numerous digital health startups. Its key differentiator is the tight integration of its own diagnostic testing, which fuels its proprietary database, creating a closed-loop ecosystem that is difficult to replicate.